Skip to main content

Table 2 Impact of patient characteristics and comorbidities on the continuation of treatment with tadalafil 5 mg OaD (N = 778)

From: Tadalafil 5 mg once daily for the treatment of erectile dysfunction during a 6-month observational study (EDATE): impact of patient characteristics and comorbidities

Population

Number of patients with

Patients without events (%), KM estimate [95 % CI]

 

Data

Events

Month 2

Month 4

Month 6

Overall (primary analysis)

773

107

94.0 [92.3,95.7]

88.3 [85.9,90.6]

86.3 [83.7,88.9]

By age

    

 Age ≤65 years

593

61

96.2 [94.7,97.8]

91.7 [89.4,93.9]

89.8 [87.1,92.4]

 Age >65 years

180

46

86.7 [81.7,91.6]

77.3 [71.1,83.5]

75.0 [68.5, 81.5]

By PDE5-I treatment

    

 PDE5-I naïve

507

71

93.9 [91.8,96.0]

88.5 [85.7,91.4]

86.1 [82.9,89.4]

 PDE5-I pretreated

265

36

94.2 [91.4,97.1]

87.6 [83.6,91.7]

86.6 [82.3,90.9]

By disease severity

    

 Mild ED

160

16

98.1 [96.0,1.00]

94.1 [90.3,97.8]

89.8 [84.4,95.3]

 Moderate ED

407

55

94.8 [92.7,97.0]

88.6 [85.5,91.8]

87.3 [83.9,90.8]

 Severe ED

203

36

89.0 [84.6,93.3]

82.8 [77.4,88.2]

80.8 [75.1,86.5]

By presence of BPH

    

 BPH present

49

10

91.8 [84.2,99.5]

87.8 [78.6,96.9]

84.9 [74.5,95.3]

 BPH absent

724

97

94.1 [92.4,95.9]

88.3 [85.9,90.7]

86.4 [83.7,89.1]

By presence of diabetes

    

 Diabetes present

123

19

93.4 [88.9,97.8]

85.3 [78.9,91.8]

84.0 [77.2,90.9]

 Diabetes absent

650

88

94.1 [92.3,95.9]

88.8 [86.3,91.3]

86.7 [83.9, 89.5]

By presence of CVD

    

 CVD present

266

41

90.9 [87.4,94.4]

86.8 [82.7,91.0]

84.6 [80.1,89.2]

 CVD absent

507

66

95.6 [93.8,97.4]

89.0 [86.2,91.8]

87.2 [84.0,90.3]

By presence of hypertension

    

 Hypertension present

258

40

91.0 [87.5,94.5]

86.8 [82.6,91.0]

84.6 [79.9,89.2]

 Hypertension absent

515

67

95.5 [93.7,97.3]

89.0 [86.2,91.8]

87.2 [84.0,90.3]

By presence of dyslipidemia

    

 Dyslipidemia present

144

24

91.6 [87.0,96.1]

86.3 [80.6,92.1]

83.5 [77.2,89.9]

 Dyslipidemia absent

629

83

94.5 [92.8,96.3]

88.7 [86.2,91.2]

87.0 [84.2,89.8]

  1. Event = Discontinuation of tadalafil OaD
  2. Note: KM estimates for subgroups with non-overlapping CIs at given time points are marked in bold
  3. BPH benign prostatic hyperplasia, CI confidence interval, CVD cardiovascular diseases, ED erectile dysfunction, KM Kaplan-Meier, N number of patients, OaD once a day, PDE5-I phosphodiesterase type 5 inhibitor